The global market for Drug Eluting Balloons (DEBs) was estimated at US$1.8 Billion in 2024 and is projected to reach US$3.4 Billion by 2030, growing at a CAGR of 11.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Drug Eluting Balloons (DEBs) market.
Global Drug Eluting Balloons (DEBs) Market - Key Trends and Drivers Summarized
What Are Drug Eluting Balloons (DEBs) and Why Are They Revolutionary in Medical Treatments?
Drug Eluting Balloons (DEBs) are an innovative class of medical devices used primarily in the treatment of peripheral and coronary artery diseases. These balloons are coated with medication that is delivered directly to the artery`s wall during the angioplasty procedure. Unlike traditional balloon angioplasty that mechanically opens the artery without delivering any therapeutic agents, DEBs provide a dual function: they not only expand the artery to alleviate blockages but also deliver a drug locally to inhibit restenosis (the re-narrowing of the artery). The primary medications used on DEBs are antiproliferative drugs, which help prevent the growth of scar tissue, thus maintaining arterial patency over time and improving patient outcomes significantly.How Do Drug Eluting Balloons Enhance Clinical Efficacy Compared to Conventional Methods?
The key advantage of drug eluting balloons over traditional treatments lies in their ability to minimize the risk of restenosis and eliminate the need for permanent implants like stents. This is particularly beneficial for patients who may be prone to stent thrombosis or those who have difficulties with long-term antiplatelet therapy. DEBs release medication that inhibits cell proliferation directly at the site of arterial injury caused by the balloon dilation, providing targeted therapeutic action while reducing systemic side effects. This local delivery system ensures a high local drug concentration immediately after the procedure, offering a more effective treatment compared to systemic drug delivery methods.What Challenges and Innovations Shape the Future of DEBs?
Despite their benefits, the development and usage of DEBs face several challenges. The primary concern is the precision of drug coating and its transfer efficiency during the procedure. Innovations in balloon technology focus on improving the homogeneity and adherence of the drug coating, ensuring that the correct dosage is delivered directly to the arterial wall. Researchers are also exploring biodegradable polymers that can control drug release rates to optimize healing. Regulatory hurdles represent another significant challenge, as the combination of device and drug into a single product requires extensive validation to meet safety and efficacy standards set by health authorities globally.What Drives the Growth in the Drug Eluting Balloons Market?
The growth in the drug eluting balloons market is driven by several factors, starting with the rising prevalence of cardiovascular diseases worldwide, which increases the demand for effective, minimally invasive treatment options. Advances in materials science have enabled the development of more efficient drug delivery systems on DEBs, enhancing their appeal to interventional cardiologists. The growing body of clinical evidence supporting the efficacy and safety of DEBs compared to conventional therapies is also compelling more healthcare providers to adopt this technology. Furthermore, the desire for treatments that reduce hospital stay durations and improve patient quality of life post-procedure boosts the adoption of DEBs. As healthcare systems increasingly focus on cost-effectiveness and better patient outcomes, the market for drug eluting balloons is expected to continue expanding, fueled by technological innovations and strategic collaborations among key industry players.SCOPE OF STUDY:
The report analyzes the Drug Eluting Balloons (DEBs) market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Product (Peripheral, Coronary); End-Use (Hospitals, Cath Labs, Ambulatory Surgery Centers)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Peripheral segment, which is expected to reach US$1.9 Billion by 2030 with a CAGR of a 9.4%. The Coronary segment is also set to grow at 14.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $486.8 Million in 2024, and China, forecasted to grow at an impressive 11.0% CAGR to reach $534.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Drug Eluting Balloons (DEBs) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Drug Eluting Balloons (DEBs) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Drug Eluting Balloons (DEBs) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Acrostak Int. Distr. Sarl, B. Braun Melsungen AG, BARD, A Becton, Dickinson Company, Cardionovum GmbH, Cook Medical, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 42 companies featured in this Drug Eluting Balloons (DEBs) market report include:
- Acrostak Int. Distr. Sarl
- B. Braun Melsungen AG
- BARD, A Becton, Dickinson Company
- Cardionovum GmbH
- Cook Medical, Inc.
- Eurocor GmbH
- Medtronic PLC
- Spectranetics Corporation
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acrostak Int. Distr. Sarl
- B. Braun Melsungen AG
- BARD, A Becton, Dickinson Company
- Cardionovum GmbH
- Cook Medical, Inc.
- Eurocor GmbH
- Medtronic PLC
- Spectranetics Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.8 Billion |
| Forecasted Market Value ( USD | $ 3.4 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Global |
